These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12796522)

  • 1. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record.
    Dalakas MC; Clark WM
    Neurology; 2003 Jun; 60(11):1736-7. PubMed ID: 12796522
    [No Abstract]   [Full Text] [Related]  

  • 2. Review: intravenous immunoglobulin therapy and thromboembolic complications.
    Katz U; Shoenfeld Y
    Lupus; 2005; 14(10):802-8. PubMed ID: 16302674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic complications of intravenous immunoglobulin treatment.
    Vucic S; Chong PS; Dawson KT; Cudkowicz M; Cros D
    Eur Neurol; 2004; 52(3):141-4. PubMed ID: 15479982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe thromboembolic complications associated with the administration of intravenous immunoglobulins.
    Gómez Pérez M; Hernández Segurado M; Bonilla Porras M; Bécares Martínez J
    Farm Hosp; 2012; 36(3):166-7. PubMed ID: 22118762
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders.
    Chun W; Kim Y; Park SH; Choi SJ
    J Clin Neurosci; 2021 Aug; 90():311-316. PubMed ID: 34275568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
    Lidar M; Masarwa S; Rotman P; Carmi O; Rabinowicz N; Levy Y
    Immunol Res; 2018 Dec; 66(6):668-674. PubMed ID: 30565202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strokes after intravenous gamma globulin: thrombotic phenomenon in patients with risk factors or just coincidence?
    Alexandrescu DT; Dutcher JP; Hughes JT; Kaplan J; Wiernik PH
    Am J Hematol; 2005 Mar; 78(3):216-20. PubMed ID: 15726606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.
    Dalakas MC
    Neurology; 1994 Feb; 44(2):223-6. PubMed ID: 8309562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies.
    Brannagan TH
    Neurology; 2002 Dec; 59(12 Suppl 6):S33-40. PubMed ID: 12499469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.
    Hefer D; Jaloudi M
    Ann Hematol; 2005 Jun; 84(6):411-5. PubMed ID: 16080234
    [No Abstract]   [Full Text] [Related]  

  • 12. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.
    Hefer D; Jaloudi M
    Ann Hematol; 2004 Oct; 83(10):661-5. PubMed ID: 15309520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin: adverse effects and safe administration.
    Orbach H; Katz U; Sherer Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical features of 16 cases of stroke associated with administration of IVIg.
    Caress JB; Cartwright MS; Donofrio PD; Peacock JE
    Neurology; 2003 Jun; 60(11):1822-4. PubMed ID: 12796539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study.
    Ramírez E; Romero-Garrido JA; López-Granados E; Borobia AM; Pérez T; Medrano N; Rueda C; Tong HY; Herrero A; Frías J
    Thromb Res; 2014 Jun; 133(6):1045-51. PubMed ID: 24731561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid infusion of intravenous immunoglobulin in patients with neuromuscular diseases.
    Gomperts ED; Darr F
    Neurology; 2002 May; 58(9):1444. PubMed ID: 12011310
    [No Abstract]   [Full Text] [Related]  

  • 17. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].
    Stangel M; Gold R
    Nervenarzt; 2011 Apr; 82(4):415-6, 418, 420 passim. PubMed ID: 20577707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of immune globulin intravenous and thromboembolic adverse events.
    Ovanesov MV; Menis MD; Scott DE; Forshee R; Anderson S; Bryan W; Golding B
    Am J Hematol; 2017 Apr; 92(4):E44-E45. PubMed ID: 28066925
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy.
    Byrne NP; Henry JC; Herrmann DN; Abdelhalim AN; Shrier DA; Francis CW; Powers JM
    Neurology; 2002 Aug; 59(3):458-61. PubMed ID: 12177388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.